A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC is a phase 2, interventional study registered as NCT07058519 by Shanghai Chest Hospital, with a registry enrolment figure of 250 participants, started 2025-09-23 and due to reach its primary completion in 2029-01-24. Interventions recorded: Osimertinib-based adaptive treatment; Osimertinib 80 MG. Conditions listed: Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC). Primary outcome: Progression-Free Survival (PFS) in Cohort 1; Time to First ctDNA EGFRm Relapse or Death in Cohort 1. Lung eligibility wording from the registry: "Newly diagnosed, and histologically documented locally advanced or metastatic non-squamous NSCLC with sensitizing EGFR mutations positive (either Exon 19 deletion or 21 L858R, confirmed by histology or cytology), and classified as stage IIIB, IIIC, IV or recurrent NSCLC which are not amenable to cur". Sites: China. No results are recorded here; the registry entry is the source.